{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:05:13Z","timestamp":1788109513041,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["42847922MDD1001"],"award-info":[{"award-number":["42847922MDD1001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Excessive arousal has a role in the pathophysiology of major depressive disorder (MDD). Seltorexant (JNJ-42847922\/MIN-202) is a selective antagonist of the human orexin-2 receptor (OX2R) that may normalize excessive arousal and thereby attenuate depressive symptoms. In this study, the effects of night-time arousal suppression on depressive symptoms were investigated. 47 MDD patients with a total Inventory of Depressive Symptomatology (IDS) score of \u226530 at screening were included in a randomized, double-blind, diphenhydramine-, and placebo-controlled multicentre study. Symptoms of depression were rated using the 17-item Hamilton Depression Rating Scale (HDRS\n                    <jats:sub>17<\/jats:sub>\n                    ). Effects on sleep were evaluated by polysomnography and by the Leeds Sleep Evaluation Questionnaire (LSEQ). To investigate the safety and tolerability of seltorexant, vital signs, suicidal ideation and adverse events were monitored. At baseline the severity of depressive symptoms correlated with sleep efficiency (SE), wake after sleep onset (WASO), duration of stage 2 sleep, and ruminations. Ten days of treatment with seltorexant (and not diphenhydramine) resulted in a significant improvement of core depressive symptoms compared to placebo; the antidepressant efficacy of seltorexant was maintained with continued treatment up to 28 days. Compared to placebo, the antidepressant efficacy of seltorexant coincided with an overall increase in (left posterior) EEG power and a relative increase in delta- and decrease in theta-, alpha- and beta power during stage 2 sleep. Treatment with seltorexant was associated with mild, self-limiting adverse drug reactions. Seltorexant affected core symptoms of depression in the absence of overt changes in the hypnogram; in contrast, diphenhydramine was not efficacious.\n                  <\/jats:p>","DOI":"10.1038\/s41398-019-0553-z","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T06:08:04Z","timestamp":1567490884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder"],"prefix":"10.1038","volume":"9","author":[{"given":"Kasper","family":"Recourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-0157","authenticated-orcid":false,"given":"Rob","family":"Zuiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Luthringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Ark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Van Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"van Nueten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Drevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"553_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069637","volume":"8","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari, A. J. et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS ONE 8, e69637 (2013).","journal-title":"PLoS ONE"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1037\/a0027474","volume":"121","author":"AJ Whitmer","year":"2012","unstructured":"Whitmer, A. J. & Gotlib, I. H. Switching and backward inhibition in major depressive disorder: The role of rumination. J. Abnorm. Psychol. 121, 570 (2012).","journal-title":"J. Abnorm. Psychol."},{"key":"553_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0022-3956(02)00021-3","volume":"36","author":"M Hatzinger","year":"2002","unstructured":"Hatzinger, M., Hemmeter, U. M., Baumann, K., Brand, S. & Holsboer-Trachsler, E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. J. Psychiatr. Res. 36, 287\u2013297 (2002).","journal-title":"J. Psychiatr. Res."},{"key":"553_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jpsychires.2004.01.010","volume":"38","author":"M Hatzinger","year":"2004","unstructured":"Hatzinger, M., Hemmeter, U. M., Brand, S., Ising, M. & Holsboer-Trachsler, E. Electroencephalographic sleep profiles in treatment course and long-term outcome of major depression: association with DEX\/CRH-test response. J. Psychiatr. Res. 38, 453\u2013465 (2004).","journal-title":"J. Psychiatr. Res."},{"key":"553_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.brainresrev.2007.04.005","volume":"57","author":"A-M Bao","year":"2008","unstructured":"Bao, A.-M., Meynen, G. & Swaab, D. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res. Rev. 57, 531\u2013553 (2008).","journal-title":"Brain Res. Rev."},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ejphar.2007.12.032","volume":"583","author":"F Holsboer","year":"2008","unstructured":"Holsboer, F. & Ising, M. Central CRH system in depression and anxiety\u2014evidence from clinical studies with CRH 1 receptor antagonists. Eur. J. Pharmacol. 583, 350\u2013357 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"553_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jad.2017.01.025","volume":"212","author":"MR Dolsen","year":"2017","unstructured":"Dolsen, M. R. et al. Neurophysiological correlates of suicidal ideation in major depressive disorder: Hyperarousal during sleep. J. Affect. Disord. 212, 160\u2013166 (2017).","journal-title":"J. Affect. Disord."},{"key":"553_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archpsyc.62.4.387","volume":"62","author":"EA Nofzinger","year":"2005","unstructured":"Nofzinger, E. A. et al. Alterations in regional cerebral glucose metabolism across waking and non\u2013rapid eye movement sleep in depression. Arch. Gen. Psychiatry 62, 387\u2013396 (2005).","journal-title":"Arch. Gen. Psychiatry"},{"key":"553_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1523\/JNEUROSCI.4734-03.2004","volume":"24","author":"Z Merali","year":"2004","unstructured":"Merali, Z. et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABAA receptor subunits in frontal cortical brain region. J. Neurosci. 24, 1478\u20131485 (2004).","journal-title":"J. Neurosci."},{"key":"553_CR10","doi-asserted-by":"crossref","unstructured":"Roth T. Insomnia: definition, prevalence, etiology, and consequences. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 3(5 Suppl) S7 (2007).","DOI":"10.5664\/jcsm.26929"},{"key":"553_CR11","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1210\/en.2011-1218","volume":"152","author":"R Yehuda","year":"2011","unstructured":"Yehuda, R. & Seckl, J. Minireview: stress-related psychiatric disorders with low cortisol levels: a metabolic hypothesis. Endocrinology 152, 4496\u20134503 (2011).","journal-title":"Endocrinology"},{"key":"553_CR12","doi-asserted-by":"crossref","unstructured":"Drevets W. C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog. Brain Res. 126, 413\u2013431 (2000).","DOI":"10.1016\/S0079-6123(00)26027-5"},{"key":"553_CR13","unstructured":"Nofzinger, E. A. & Keshavan, M. Sleep disturbances associated with neuropsychiatric disease. In Neuropsychopharmacology: The Fifth Generation of Progress (eds Davis, K. L., Charney, D., Coyle, J. T. & Nemeroff, C.) (American College of Neuropsychopharmacology, 2002)."},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.mp.4001032","volume":"7","author":"P Gold","year":"2002","unstructured":"Gold, P. & Chrousos, G. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH\/NE states. Mol. Psychiatry 7, 254 (2002).","journal-title":"Mol. Psychiatry"},{"key":"553_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0006-3223(97)00484-8","volume":"43","author":"JF L\u00f3pez","year":"1998","unstructured":"L\u00f3pez, J. F., Chalmers, D. T., Little, K. Y. & Watson, S. J. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 43, 547\u2013573 (1998).","journal-title":"Biol. Psychiatry"},{"key":"553_CR16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.nucmedbio.2007.06.008","volume":"34","author":"WC Drevets","year":"2007","unstructured":"Drevets, W. C. et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 34, 865\u2013877 (2007).","journal-title":"Nucl. Med. Biol."},{"key":"553_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.brainres.2009.09.019","volume":"1314","author":"CW Berridge","year":"2010","unstructured":"Berridge, C. W., Espa\u00f1a, R. A. & Vittoz, N. M. Hypocretin\/orexin in arousal and stress. Brain Res. 1314, 91\u2013102 (2010).","journal-title":"Brain Res."},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"553_CR19","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1523\/JNEUROSCI.1887-05.2005","volume":"25","author":"MG Lee","year":"2005","unstructured":"Lee, M. G., Hassani, O. K. & Jones, B. E. Discharge of identified orexin\/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 25, 6716\u20136720 (2005).","journal-title":"J. Neurosci."},{"key":"553_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.neuroscience.2008.02.058","volume":"153","author":"K Takahashi","year":"2008","unstructured":"Takahashi, K., Lin, J.-S. & Sakai, K. Neuronal activity of orexin and non-orexin waking-active neurons during wake\u2013sleep states in the mouse. Neuroscience 153, 860\u2013870 (2008).","journal-title":"Neuroscience"},{"key":"553_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.neuropharm.2011.04.022","volume":"61","author":"M Nollet","year":"2011","unstructured":"Nollet, M. et al. Activation of orexin neurons in dorsomedial\/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 61, 336\u2013346 (2011).","journal-title":"Neuropharmacology"},{"key":"553_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnbeh.2017.00083","volume":"11","author":"S Yun","year":"2017","unstructured":"Yun, S. et al. Selective inhibition of orexin-2 receptors prevents stress-induced ACTH release in mice. Front. Behav. Neurosci. 11, 83 (2017).","journal-title":"Front. Behav. Neurosci."},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1046\/j.1365-2826.2000.00572.x","volume":"12","author":"M Jaszberenyi","year":"2000","unstructured":"Jaszberenyi, M., Bujdoso, E., Pataki, I. & Telegdy, G. Effects of orexins on the hypothalamic\u2010pituitary\u2010adrenal system. J. Neuroendocrinol. 12, 1174\u20131178 (2000).","journal-title":"J. Neuroendocrinol."},{"key":"553_CR24","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/00001756-200006260-00034","volume":"11","author":"M Kuru","year":"2000","unstructured":"Kuru, M. et al. Centrally administered orexin\/hypocretin activates HPA axis in rats. Neuroreport 11, 1977\u20131980 (2000).","journal-title":"Neuroreport"},{"key":"553_CR25","doi-asserted-by":"publisher","first-page":"R382","DOI":"10.1152\/ajpregu.00496.2006","volume":"292","author":"WK Samson","year":"2007","unstructured":"Samson, W. K., Bagley, S. L., Ferguson, A. V. & White, M. M. Hypocretin\/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress. Am. J. Physiol. Regul., Integr. Comp. Physiol. 292, R382\u2013R387 (2007).","journal-title":"Am. J. Physiol. Regul., Integr. Comp. Physiol."},{"key":"553_CR26","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/npp.2012.70","volume":"37","author":"M Nollet","year":"2012","unstructured":"Nollet, M. et al. Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 37, 2210 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"553_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.smrv.2004.07.006","volume":"9","author":"WK Samson","year":"2005","unstructured":"Samson, W. K., Taylor, M. M. & Ferguson, A. V. Non-sleep effects of hypocretin\/orexin. Sleep. Med. Rev. 9, 243\u2013252 (2005).","journal-title":"Sleep. Med. Rev."},{"key":"553_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/ijcp.12568","volume":"68","author":"L Citrome","year":"2014","unstructured":"Citrome, L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic\u2013what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 68, 1429\u20131441 (2014).","journal-title":"Int. J. Clin. Pract."},{"key":"553_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ijnp\/pyx033","volume":"20","author":"KM Connor","year":"2017","unstructured":"Connor, K. M. et al. Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 20, 613\u2013618 (2017).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"553_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0006-3223(95)00188-3","volume":"39","author":"N Breslau","year":"1996","unstructured":"Breslau, N., Roth, T., Rosenthal, L. & Andreski, P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol. psychiatry 39, 411\u2013418 (1996).","journal-title":"Biol. psychiatry"},{"key":"553_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jpsychires.2006.07.008","volume":"40","author":"EO Johnson","year":"2006","unstructured":"Johnson, E. O., Roth, T. & Breslau, N. The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J. Psychiatr. Res. 40, 700\u2013708 (2006).","journal-title":"J. Psychiatr. Res."},{"key":"553_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jpsychores.2007.10.016","volume":"64","author":"M Jansson-Fr\u00f6jmark","year":"2008","unstructured":"Jansson-Fr\u00f6jmark, M. & Lindblom, K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. J. Psychosom. Res. 64, 443\u2013449 (2008).","journal-title":"J. Psychosom. Res."},{"key":"553_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4088\/JCP.09m05218gry","volume":"71","author":"JG van Mill","year":"2010","unstructured":"van Mill, J. G., Hoogendijk, W. J., Vogelzangs, N., van Dyck, R. & Penninx, B. W. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J. Clin. Psychiatry 71, 239 (2010).","journal-title":"J. Clin. Psychiatry"},{"key":"553_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/15622970802503086","volume":"10","author":"J Mendlewicz","year":"2009","unstructured":"Mendlewicz, J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J. Biol. Psychiatry 10, 269\u2013275 (2009).","journal-title":"World J. Biol. Psychiatry"},{"key":"553_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnins.2014.00028","volume":"8","author":"C Dugovic","year":"2014","unstructured":"Dugovic, C. et al. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front. Neurosci. 8, 28 (2014).","journal-title":"Front. Neurosci."},{"key":"553_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nrn808","volume":"3","author":"JG Sutcliffe","year":"2002","unstructured":"Sutcliffe, J. G. & de Lecea, L. The hypocretins: setting the arousal threshold. Nat. Rev. Neurosci. 3, 339 (2002).","journal-title":"Nat. Rev. Neurosci."},{"key":"553_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/jpet.109.152009","volume":"330","author":"C Dugovic","year":"2009","unstructured":"Dugovic, C. et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142\u2013151 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"553_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","volume":"38","author":"JT Willie","year":"2003","unstructured":"Willie, J. T. et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38, 715\u2013730 (2003).","journal-title":"Neuron"},{"key":"553_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","volume":"354","author":"P Bonaventure","year":"2015","unstructured":"Bonaventure, P. et al. Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J. Pharmacol. Exp. Ther. 354, 471\u2013482 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"553_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0269881118822258","volume":"33","author":"Sander Brooks","year":"2019","unstructured":"Brooks, S. et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J. Psychopharmacol. 33, 202\u2013209 (2019).","journal-title":"Journal of Psychopharmacology"},{"key":"553_CR41","doi-asserted-by":"crossref","unstructured":"De Boer, P. et al. A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J. Psychopharmacol. 32, 668\u2013677 (2018).","DOI":"10.1177\/0269881118773745"},{"key":"553_CR42","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1177\/0269881118791521","volume":"32","author":"PD van der Ark","year":"2018","unstructured":"van der Ark, P. D., Golor, G., van Nueten, L., Nandy, P. & de Boer, P. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J. Psychopharmacol. 32, 1330\u20131340 (2018).","journal-title":"J. Psychopharmacol."},{"key":"553_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56 (1960).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"553_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"MH Trivedi","year":"2004","unstructured":"Trivedi, M. H. et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 34, 73\u201382 (2004).","journal-title":"Psychol. Med."},{"key":"553_CR45","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1037\/0021-843X.109.3.504","volume":"109","author":"S Nolen-Hoeksema","year":"2000","unstructured":"Nolen-Hoeksema, S. The role of rumination in depressive disorders and mixed anxiety\/depressive symptoms. J. Abnorm. Psychol. 109, 504 (2000).","journal-title":"J. Abnorm. Psychol."},{"key":"553_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S0033291700014379","volume":"8","author":"A Parrott","year":"1978","unstructured":"Parrott, A. & Hindmarch, I. Factor analysis of a sleep evaluation questionnaire. Psychol. Med. 8, 325\u2013329 (1978).","journal-title":"Psychol. Med."},{"key":"553_CR47","doi-asserted-by":"crossref","unstructured":"Posner, K. et al. Columbia-Suicide Severity Rating Scale (C-SSRS) (Columbia University Medical Center, New York, 2008).","DOI":"10.1037\/t52667-000"},{"key":"553_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0006-3223(02)01740-7","volume":"54","author":"RM Salomon","year":"2003","unstructured":"Salomon, R. M. et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96\u2013104 (2003).","journal-title":"Biol. Psychiatry"},{"key":"553_CR49","doi-asserted-by":"crossref","unstructured":"Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. A Meta-Analysis of Antidepressant Outcome Under \u201cBlinder\u201d Conditions (American Psychological Association, 1992).","DOI":"10.1037\/0022-006X.60.5.664"},{"key":"553_CR50","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.cpr.2010.06.001","volume":"30","author":"P Cuijpers","year":"2010","unstructured":"Cuijpers, P., Li, J., Hofmann, S. G. & Andersson, G. Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. Clin. Psychol. Rev. 30, 768\u2013778 (2010).","journal-title":"Clin. Psychol. Rev."}],"updated-by":[{"DOI":"10.1038\/s41398-019-0585-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000}}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0553-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T10:44:11Z","timestamp":1671187451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0553-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"21 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original Article, Tables two and three had formatting issues which affected their clarity. This has been corrected in the PDF and HTML versions of this Article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study was funded by Janssen Research and Development, which also provided the study medication. P.d.B., P.v.d.A., I.V.H. and L.v.N., and W.C.D. are employees of Janssen and own Johnson and Johnson equity. J.K. is an employee of Sunovion, and owns Sunovion equity. R.L. is a Minerva Neurosciences employee and owns Minerva Neurosciences equity. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"216"}}